372 related articles for article (PubMed ID: 23954510)
1. Inclusion of fenofibrate in a series of mesoporous silicas using microwave irradiation.
Waters LJ; Hussain T; Parkes G; Hanrahan JP; Tobin JM
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):936-41. PubMed ID: 23954510
[TBL] [Abstract][Full Text] [Related]
2. Development of novel core-shell dual-mesoporous silica nanoparticles for the production of high bioavailable controlled-release fenofibrate tablets.
Zhao Z; Gao Y; Wu C; Hao Y; Zhao Y; Xu J
Drug Dev Ind Pharm; 2016; 42(2):199-208. PubMed ID: 26114553
[TBL] [Abstract][Full Text] [Related]
3. A novel strategy to design sustained-release poorly water-soluble drug mesoporous silica microparticles based on supercritical fluid technique.
Li-Hong W; Xin C; Hui X; Li-Li Z; Jing H; Mei-Juan Z; Jie L; Yi L; Jin-Wen L; Wei Z; Gang C
Int J Pharm; 2013 Sep; 454(1):135-42. PubMed ID: 23871738
[TBL] [Abstract][Full Text] [Related]
4. Exploitation of 3D face-centered cubic mesoporous silica as a carrier for a poorly water soluble drug: influence of pore size on release rate.
Zhu W; Wan L; Zhang C; Gao Y; Zheng X; Jiang T; Wang S
Mater Sci Eng C Mater Biol Appl; 2014 Jan; 34():78-85. PubMed ID: 24268236
[TBL] [Abstract][Full Text] [Related]
5. Impact of surface area of silica particles on dissolution rate and oral bioavailability of poorly water soluble drugs: a case study with aceclofenac.
Kumar D; Sailaja Chirravuri SV; Shastri NR
Int J Pharm; 2014 Jan; 461(1-2):459-68. PubMed ID: 24368106
[TBL] [Abstract][Full Text] [Related]
6. Dissolution-rate enhancement of fenofibrate by adsorption onto silica using supercritical carbon dioxide.
Sanganwar GP; Gupta RB
Int J Pharm; 2008 Aug; 360(1-2):213-8. PubMed ID: 18550302
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of novel core-shell structured dual-mesoporous silica nanospheres and their application for enhancing the dissolution rate of poorly water-soluble drugs.
Wu C; Sun X; Zhao Z; Zhao Y; Hao Y; Liu Y; Gao Y
Mater Sci Eng C Mater Biol Appl; 2014 Nov; 44():262-7. PubMed ID: 25280705
[TBL] [Abstract][Full Text] [Related]
8. Ketoprofen mesoporous silica nanoparticles SBA-15 hard gelatin capsules: preparation and in vitro/in vivo characterization.
Abd-Elrahman AA; El Nabarawi MA; Hassan DH; Taha AA
Drug Deliv; 2016 Nov; 23(9):3387-3398. PubMed ID: 27167529
[TBL] [Abstract][Full Text] [Related]
9. Novel scheme for rapid synthesis of hollow mesoporous silica nanoparticles (HMSNs) and their application as an efficient delivery carrier for oral bioavailability improvement of poorly water-soluble BCS type II drugs.
Li T; Geng T; Md A; Banerjee P; Wang B
Colloids Surf B Biointerfaces; 2019 Apr; 176():185-193. PubMed ID: 30616109
[TBL] [Abstract][Full Text] [Related]
10. Preparation, characterization, and evaluation in vivo of Ins-SiO₂-HP55 (insulin-loaded silica coating HP55) for oral delivery of insulin.
Zhao X; Shan C; Zu Y; Zhang Y; Wang W; Wang K; Sui X; Li R
Int J Pharm; 2013 Sep; 454(1):278-84. PubMed ID: 23830939
[TBL] [Abstract][Full Text] [Related]
11. Dissolution enhancement of a model poorly water-soluble drug, atorvastatin, with ordered mesoporous silica: comparison of MSF with SBA-15 as drug carriers.
Maleki A; Hamidi M
Expert Opin Drug Deliv; 2016; 13(2):171-81. PubMed ID: 26636904
[TBL] [Abstract][Full Text] [Related]
12. Dodecylamine Template-Based Hexagonal Mesoporous Silica (HMS) as a Carrier for Improved Oral Delivery of Fenofibrate.
Jadhav NV; Vavia PR
AAPS PharmSciTech; 2017 Oct; 18(7):2764-2773. PubMed ID: 28353172
[TBL] [Abstract][Full Text] [Related]
13. Biomimetic synthesized nanoporous silica@poly(ethyleneimine)s xerogel as drug carrier: characteristics and controlled release effect.
Li J; Xu L; Liu H; Wang Y; Wang Q; Chen H; Pan W; Li S
Int J Pharm; 2014 Jun; 467(1-2):9-18. PubMed ID: 24674897
[TBL] [Abstract][Full Text] [Related]
14. Use of SBA-15 for furosemide oral delivery enhancement.
Ambrogi V; Perioli L; Pagano C; Marmottini F; Ricci M; Sagnella A; Rossi C
Eur J Pharm Sci; 2012 May; 46(1-2):43-8. PubMed ID: 22365882
[TBL] [Abstract][Full Text] [Related]
15. Drug release property of chitosan-pectinate beads and its changes under the influence of microwave.
Wong TW; Nurjaya S
Eur J Pharm Biopharm; 2008 May; 69(1):176-88. PubMed ID: 17980563
[TBL] [Abstract][Full Text] [Related]
16. Drug delivery formulations of ordered and nonordered mesoporous silica: comparison of three drug loading methods.
Limnell T; Santos HA; Mäkilä E; Heikkilä T; Salonen J; Murzin DY; Kumar N; Laaksonen T; Peltonen L; Hirvonen J
J Pharm Sci; 2011 Aug; 100(8):3294-3306. PubMed ID: 21520084
[TBL] [Abstract][Full Text] [Related]
17. Molecular-level insight into hot-melt loading and drug release from mesoporous silica carriers.
Lizoňová D; Mužík J; Šoltys M; Beránek J; Kazarian SG; Štěpánek F
Eur J Pharm Biopharm; 2018 Sep; 130():327-335. PubMed ID: 30012403
[TBL] [Abstract][Full Text] [Related]
18. Enhanced oral bioavailability of novel mucoadhesive pellets containing valsartan prepared by a dry powder-coating technique.
Cao QR; Liu Y; Xu WJ; Lee BJ; Yang M; Cui JH
Int J Pharm; 2012 Sep; 434(1-2):325-33. PubMed ID: 22688251
[TBL] [Abstract][Full Text] [Related]
19. [Preparation and release behaviour of mesoporous silica/ethylcellulose sustained-release mini-matrix].
Wu QL; Quan GL; Hong Y; Wu LN; Zeng YM; Li G; Pan X; Wu CB
Yao Xue Xue Bao; 2015 Apr; 50(4):492-9. PubMed ID: 26223134
[TBL] [Abstract][Full Text] [Related]
20. High drug load, stable, manufacturable and bioavailable fenofibrate formulations in mesoporous silica: a comparison of spray drying versus solvent impregnation methods.
Hong S; Shen S; Tan DC; Ng WK; Liu X; Chia LS; Irwan AW; Tan R; Nowak SA; Marsh K; Gokhale R
Drug Deliv; 2016; 23(1):316-27. PubMed ID: 24853963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
